When was Precision BioSciences founded?

Precision BioSciences was founded in 2006 and raised its 1st funding round 2 years after it was founded.

Where is Precision BioSciences located?

Precision BioSciences is headquartered in Durham, United States. It is registered at Durham, North Carolina.

Who is the current CEO of Precision BioSciences?

Matthew Kane of Precision BioSciences.

How many employees does Precision BioSciences have?

As of Sep 30, 2026, the latest employee count at Precision BioSciences is 100.

Is Precision BioSciences a funded company?

Precision BioSciences is a funded company, having raised a total of $136M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 12, 2008.

When was the latest funding round of Precision BioSciences?

Precision BioSciences' latest funding was a $***** Post IPO round on Mar 03, 2026, with participation from 0 investor.

What is the annual revenue of Precision BioSciences?

Annual revenue of Precision BioSciences is between $10M and $50M as on Dec 31, 2025

Where does Precision BioSciences rank among its competitors?

Precision BioSciences ranks 322nd amongst 3548 active competitors, of which 1214 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Precision BioSciences?

Precision BioSciences' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Precision BioSciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Precision BioSciences is a public company based in Durham (United States), founded in 2006. It operates as a Developer of gene editing therapies to treat rare genetic diseases. Precision BioSciences has raised $136M in funding from VenBio and ArrowMark Partners. The company has 3548 active competitors, including 1214 funded and 820 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.

Website: precisionbiosciences.com
Registered Address: Durham, North Carolina

Key Metrics

Founded Year

2006

Location

Durham, United States

Stage

Public

Total Funding

$136M in 9 rounds

Latest Funding Round

Post IPO, Mar 03, 2026, $*****

Investors

VenBio & 30 more

Ranked

322^nd among 3548 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

100 as on Sep 30, 2026

Similar Companies

BeiGene & 980 more

Exit Details

Public

View Precision BioSciences' full profile

Precision BioSciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Precision Biosciences, Inc. CIN: 20201021772 , United States, Active	Jan 08, 2020	-	-	-
PRECISION BIOSCIENCES INC CIN: 1357874 , United States, Active	Jan 25, 2006	$10M - $50M (As on Dec 31, 2025)	-	-
Precision Biosciences, Inc. CIN: 204206017 , United States, Active	Dec 26, 999	-	113 (As on Dec 31, 2024)	-

Precision BioSciences got listed on Mar 28, 2019.

Click here to take a look at Precision BioSciences's IPO in detail

Precision BioSciences has raised a total funding of $136M over 9 rounds. Its first funding round was on Feb 12, 2008. Precision BioSciences has 31 institutional investors.

Here is the list of recent funding rounds of Precision BioSciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 03, 2026	4142964	Post IPO	5533602	3263414	5875201	4089890
Jun 24, 2022	2946847	Post IPO	8109840	3529987	8099540	Novartis
Mar 14, 2019	4835040	Conventional Debt	9364151	1664953	9871672	6704415

Access funding benchmarks and valuations. Sign up today!

View details of Precision BioSciences's funding rounds and investors

Precision BioSciences' employee count trend

Precision BioSciences has 100 employees as of Sep 26. Here is Precision BioSciences's employee count trend over the years:

Employee count trend for Precision BioSciences

Uncover Precision BioSciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Precision BioSciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Precision BioSciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
322nd	Precision BioSciences 2006, Durham (United States), Public	Developer of gene editing therapies to treat rare genetic diseases	$136M	Amgen Business Development, ArrowMark Partners ... & 29 others	57/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Precision BioSciences's competitors? Click here to see the top ones

Precision BioSciences has made no investments or acquisitions yet.

Here is the latest report on Precision BioSciences's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Precision BioSciences

Media has covered Precision BioSciences for a total of 31 events in the last 1 year, 17 of them have been about company updates and 1 about people movement.